Choosing between the two molecules is the decision a reader makes before choosing a seller, and it has a price attached that is remarkably consistent. Comparing the two inside each seller that publishes both — rather than across two corpus medians — gives the number that applies to an actual purchase.
What the premium is
Of 380 sellers publishing both injected molecules, 341 charge more for tirzepatide, 33 charge the same, and 6 charge less. The median premium is $60 a month, with the middle half running $40 to $100 and the full range from $-50 to $270.
Over a year the median premium comes to $720. That is a real sum and a smaller one than the gap between the cheapest and dearest seller for either molecule, which is the comparison worth making first.
What the premium is not
It is not a judgment about whether tirzepatide is worth the money. That is a question about evidence rather than pricing, and the trial comparison is in what the tirzepatide premium buys. Nothing in this census says the premium is deserved or undeserved; it says what it is.
It is also not a reason to choose a molecule on price alone. The severe side-effect profiles were indistinguishable in the largest head-to-head safety comparison, which we cover in paying more for fewer side effects, so tolerability is not the tiebreaker a reader might expect either.
How to use it
As a sense check. If a seller quotes a tirzepatide premium far outside $40 to $100, that is worth noticing — in either direction. A premium well above the range may be pricing something the page has not explained; a premium well below may indicate a microdose tier rather than a bargain, which is the distinction drawn in the dose people actually stay on. Roster read September 2026.